Skip to Main Content

Paper Details

Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma.
J Immunother Cancer
4
2022
CD127, CD127-GARP- T cells, CD3, CD38, CD39, CD4, CD8+ T, GARP, IPI, NIVO, NIVO 1, NIVO 3, Patients, RNA, STAT, STAT5, T-cell, ectoenzyme-expressing T cells, ipilimumab, melanoma, nivolumab, patients, peripheral T cells, programmed cell-death 1, signal-transducer-and-activator-of-transcription (STAT)2, stages IIIB/IIIC/IV melanoma
Author NameAffiliation
Judith D GoldbergLaura and Isaac Perlmutter Cancer Center
Judith D GoldbergNYU Grossman School of Medicine
Judith D GoldbergLaura and Isaac Perlmutter Cancer Center
Judith D GoldbergNYU Grossman School of Medicine
Anna C PavlickLaura and Isaac Perlmutter Cancer Center
  • 1 - 5

Datasets

Release 1.2